In a post hoc analysis of the MIRROR randomized controlled trial, 47% of patients with gout treated with pegloticase over 52 weeks were able to achieve remission. These data revealed patients may benefit from being treated with the drug longer than 6 months.

“The harmful effects of gout are apparent with growing evidence supporting detrimental musculoskeletal and systemic health consequences of this condition, particularly of acute gout flares,” wrote a team of investigators led by Yael Klionsky, MD, clinical assistant professor, Rheumatology and Immunology, at Wake Forest University School of Medicine. “Akin to treatment goals of other rheumatic diseases, the concept of treating gout to remission is important for improving patient care and better understanding its impact on patient quality of life (QoL).”

Source: MDMag

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

https://www.hcplive.com/view/gout-remission-achieved-in-approximately-half-of-patients-treated-with-pegloticase